5.32
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunesis Pharmaceuticals Inc | SNSS | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 5.32 | 19:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.32 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
4.72 | 4.75 | 0.03 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 5.32 | USD |
Sunesis Pharmaceuticals Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 96.34M | 18.11M | 17.59M | $ 2.07M | $ - | -2.89 | -1.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Sunesis Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNSS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 3.10 | 7.0864 | 2.89 | 4.81 | 8,935,077 | 2.22 | 71.61% |
3 Months | 1.76 | 7.0864 | 1.73 | 4.26 | 3,102,318 | 3.56 | 202.27% |
6 Months | 1.33 | 7.0864 | 1.12 | 3.44 | 1,925,697 | 3.99 | 300.0% |
1 Year | 1.02 | 7.0864 | 0.161 | 0.911192 | 4,998,883 | 4.30 | 421.57% |
3 Years | 7.05 | 7.69 | 0.161 | 0.9030045 | 2,191,658 | -1.73 | -24.54% |
5 Years | 0.711 | 7.69 | 0.161 | 0.9660162 | 1,394,241 | 4.61 | 648.24% |
Sunesis Pharmaceuticals Description
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements. |